Company intelligence / Profile preview

Advagene Biopharma Co., Ltd.

Taipei, Taipei City, Taiwan

Ownership: Private
Employees: ~12
Development stage: Other

Overview

The company has completed Phase II clinical trials for its nasal spray influenza vaccine (LT-Flu) confirming safety and effectiveness. Phase I/II human clinical trials for dust mite allergic rhinitis treatment were completed in 2021. Phase II clinical trials for eosinophilic asthma treatment were initiated in 2023. COVID-19 immunotherapy Phase II trials in Taiwan and Phase II/III in Indonesia were initiated in 2021.

Therapeutic areas: ImmunologyPulmonologyInfectious Diseases
Modalities: Recombinant proteinVaccinesImmunotherapy
Industry: Biotech

Drug pipeline

9 assets

inactivated trivalent influenza vaccine (Sanofi) (Sanofi)

Approved

8 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Advagene Biopharma Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advagene Biopharma Co., Ltd..

Explore the full profile